ClinicalTrials.gg
CompletedNCT02444572ENOXACAREUpdated Jul 29, 2021

Comparison of Thromboembolic Events in Patients Undergoing Thromboprophylactic Treatment With ENOXA® vs Lovenox®

A Phase 4 interventional study of Enoxaparin 4000 IU in Gastrointestinal Neoplasms and Thromboembolic Event, sponsored by Les Laboratoires des Médicaments Stériles. Completed at 1 site in Tunisia. Open to participants aged 19 Years to 90 Years. Per ClinicalTrials.gov, last updated 2021-07-29.

Sponsored by Les Laboratoires des Médicaments Stériles · Phase 4, Interventional, and Prevention

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
168
Allocation
Randomized
Ages
19 Years to 90 Years
Sex
All
01

Study summary

Prospective, monocentric, randomized, parallel group, rater-blinded study using two formulations of Enoxaparin sodium (ENOXA® vs LOVENOX®) to compare the thromboembolic events (symptomatic and asymptomatic) in patients undergoing gastrointestinal cancer surgery and thromboprophylactic treatment with either Enoxaparin formulations.

The study has a secondary focus as to evaluate the immunogenicity of the two formulations of Enoxaparin through a subgroup analysis.

Study followup duration is up to 30 days post surgical procedure.

02

Conditions studied

  • Gastrointestinal Neoplasms
  • Thromboembolic Event

Keywords

  • Enoxaparin
  • Immunogenicity
03

In context

Gastrointestinal Neoplasms

696 studies on the registry are indexed under Gastrointestinal Neoplasms; 210 are open to participants now.

This study's enrollment of 168 is above the median of 74 across 495 interventional studies indexed under Gastrointestinal Neoplasms.

Browse Gastrointestinal Neoplasms studies →

Lead sponsor

Les Laboratoires des Médicaments Stériles is the lead sponsor of 13 studies on the registry; 3 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
19 Years to 90 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Male or female over 18 years
  • Gastrointestinal (GI) Cancer
  • Elective or emergency surgery
  • Preventive administration of enoxaparin sodium

Exclusion criteria

Exclusion Criteria:

  • Patients participating in another study
  • Unfractionated heparin (UFH) use up to 30 days prior to surgical procedure
  • Renal failure with \<30 ml / min
  • Known history of peripheral venous thrombosis and/or deep venous thrombosis in the 3 months prior to inclusion
  • Pregnant or breastfeeding women or women of childbearing age not using medically accepted method
  • Anticoagulant use in the 3 months prior to inclusion
  • Patients with known haemostatic disorder
  • Patients not consenting to participate in the study, or not capable of understanding its objectives
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

05

Study design

Phase
Phase 4
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Outcomes assessor)
Enrollment
168 participants (actual)

Study arms

  • Experimental
    ENOXA® group

    Patients under ENOXA® 4000 IU according to randomization: * Administer ENOXA® 4000 IU (Enoxaparin 4000 IU) per day, regardless of the patient's weight at inclusion * Start injections 12 hours after the surgical procedure * Administer ENOXA® subcutaneously * The administration of ENOXA® should be at the same time on a daily basis for 30 successive days as per the american and french clinical guidelines

    Drug: Enoxaparin 4000 IU

  • Active comparator
    LOVENOX® group

    Patients under LOVENOX® 4000 IU according to randomization: * Administer LOVENOX® 4000 IU (Enoxaparin 4000 IU) per day, regardless of the patient's weight at inclusion * Start injections 12 hours after the surgical procedure * Administer LOVENOX® subcutaneously * The administration of LOVENOX® should be at the same time on a daily basis for 30 successive days as per the american and french clinical guidelines

    Drug: Enoxaparin 4000 IU

Interventions

06

What researchers measure

Primary outcomes

  1. Incidence of asymptomatic Deep Venous Thrombosis (DVT)

    To compare the incidence of asymptomatic DVT, assessed by Echo Doppler of the lower limbs, between the two study treatment arms

    Time frame: 7 - 10 days postoperative

Secondary outcomes

  1. Incidence of symptomatic thromboembolic events

    Compare the incidence of symptomatic DVT and pulmonary embolism (PE) between the two study treatment arms

    Time frame: 30 days postoperative

  2. Number of adverse events

    To compare the safety of both the study of products

    Time frame: 30 days postoperative

  3. Incidence of both Enoxaparin formulations immunogenicity

    To compare the levels of platelet factor 4 (PF4)-Heparin complex antibodies an platelet count between the two study treatment arms

    Time frame: 0 -10 days postoperative

07

Study locations

1 site
  • Charles Nicolle Hospital
    Tunis, Tunis BAB Souika 1006, Tunisia
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Oct 2015 to primary completion in Jul 2020, 57 months.

How these figures are worked out, and which studies are left out of them.

Registered
May 7, 2015
First posted
May 14, 2015
StartActual
Oct 2015
Primary completionActual
Jul 2020
CompletionActual
Jul 10, 2020
Last update
Jul 29, 2021
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 29, 2021, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT02444572
Lead sponsor
Les Laboratoires des Médicaments Stériles
Responsible party
Sponsor
First posted
May 14, 2015
Start date
Oct 2015
Primary completion
Jul 2020
Completion
Jul 10, 2020
Last update
Jul 29, 2021

Study contacts

Chadli DZIRI, MD
principal investigator · Charles Nicolle Hospital

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jul 2021. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Enoxaparin

Start the discussion